Edition:
United States

DBV Technologies SA (DBVT.OQ)

DBVT.OQ on NASDAQ Stock Exchange Global Select Market

21.48USD
11:02am EST
Change (% chg)

$0.02 (+0.09%)
Prev Close
$21.46
Open
$21.63
Day's High
$21.69
Day's Low
$21.42
Volume
24,237
Avg. Vol
131,307
52-wk High
$50.40
52-wk Low
$20.59

Latest Key Developments (Source: Significant Developments)

DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product
Monday, 20 Nov 2017 02:20am EST 

Nov 20 (Reuters) - DBV TECHNOLOGIES SA ::SAYS STUDY DEMONSTRATES GOOD TOLERANCE AND SAFETY OF PRODUCT, COMPARABLE TO PREVIOUS STUDIES.FIST PERIOD OF STUDY COMPARED SAFETY OF TREATMENT WITH VIASKIN PEANUT 250 ΜG TO PLACEBO FOR 6 MTHS.RESULTS WILL SERVE AS A BASIS FOR PLANNED DISCUSSIONS WITH REGULATORY AUTHORITIES.SOME SERIOUS ADVERSE EVENTS WERE OBSERVED IN THE TRIAL.PATIENTS WHO COMPLETED FIRST PART OF STUDY WILL RECEIVE ACTIVE TREATMENT FOR 36 MTHS.  Full Article

DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​
Tuesday, 14 Nov 2017 11:30am EST 

Nov 14 (Reuters) - DBV TECHNOLOGIES SA ::‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​.‍PRIMARY ENDPOINT OF PHASE IIB STUDY WAS MET AFTER 12 MONTHS OF TREATMENT​.‍LONG-TERM EXTENSION DATA SHOWED TREATMENT BENEFIT INCREASES OVER TIME​.‍ONGOING VIASKIN PEANUT PHASE III PROGRAM INCLUDES THREE GLOBAL STUDIES IN CHILDREN​.  Full Article

DBV Technologies reports at Sept. 30 cash position of 170.5 million euros
Tuesday, 31 Oct 2017 12:58pm EDT 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​.  Full Article

DBV Technologies ‍cash position of 170.5 million euros as of September 30​
Tuesday, 31 Oct 2017 02:44am EDT 

Oct 31 (Reuters) - DBV TECHNOLOGIES SA ::‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016.​.  Full Article

DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study
Friday, 20 Oct 2017 05:41pm EDT 

Oct 20 (Reuters) - Dbv Technologies Sa :DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​.DBV Technologies - topline results show statistically significant response with a favorable tolerability profile.DBV Technologies - primary endpoint did not reach 15% lower bound of CI that was proposed in study’s statistical analysis plan‍​.DBV Technologies - DBV will continue ongoing discussions with FDA, and plans to proceed with the BLA preparation process.  Full Article

DBV Technologies initiates phase III study of Viaskin peanut
Wednesday, 2 Aug 2017 01:30am EDT 

Aug 2 (Reuters) - DBV TECHNOLOGIES SA :REG-DBV TECHNOLOGIES INITIATES PHASE III STUDY OF VIASKIN PEANUT IN PEANUT-ALLERGIC PATIENTS ONE TO THREE YEARS OF AGE.  Full Article

DBV Technologies H1 net loss widens to EUR 72.5 million
Friday, 28 Jul 2017 01:30am EDT 

July 28 (Reuters) - DBV TECHNOLOGIES SA ::CASH POSITION: CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2017, WERE €198.7 MILLION‍​.OPERATING INCOME: OPERATING INCOME WAS €7.6 MILLION FOR THE FIRST HALF 2017 COMPARED TO €4.8 MILLION FOR THE PRIOR-YEAR PERIOD.NET LOSS: NET LOSS WAS €72.5 MILLION FOR THE FIRST HALF 2017, COMPARED TO €49.4 MILLION FOR THE FIRST HALF 2016..  Full Article

Dbv Technologies cash position shrinks to EUR 227.0 mln
Friday, 28 Apr 2017 01:30am EDT 

April 28 (Reuters) - DBV Technologies SA ::Cash and cash equivalents amounted to EUR 227.0 million ($246.5 million) as of March 31, 2017 compared to EUR 256.5 million as of Dec 31, 2016.  Full Article

DBV Technologies FY net loss widens to 114.5 mln euros
Wednesday, 15 Mar 2017 02:30am EDT 

DBV Technologies SA : FY net loss of amounts to 114.5 million euros versus a loss of 44.7 million euros a year ago . FY operating income is 9.1 million euros versus 6.2 million euros a year ago .Net cash flows from financing activities were 1.7 million euros in 2016 compared to 241.0 million euros in 2015.  Full Article

DBV Technologies announces completion of enrollment of the realise study in peanut allergic children
Friday, 10 Mar 2017 01:30am EST 

DBV Technologies Sa : Reg-DBV Technologies announces completion of enrollment of the realise study in peanut allergic children . Higher-Than-Expected patient demand leads to increased randomization target .Global PHASE III program results expected in second half 2017.  Full Article

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​